Provention bio receives complete response letter (crl) to biologics license application (bla) for teplizumab for the delay of clinical type 1 diabetes (t1d) in at-risk individuals

Red bank, n.j., july 6, 2021 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the u.s. food and drug administration (fda) has issued a complete response letter (crl) for the company's biologics license application (bla) for teplizumab for the delay of clinical type 1 diabetes (t1d) in at-risk individuals.
PRVB Ratings Summary
PRVB Quant Ranking